Migraine Device Study

Do You Get Migraine?

NOW ENROLLING FOR A LOCAL INVESTIGATIONAL STUDY

Searching for people ages 18-65 who've been diagnosed with Migraine!

SIGN UP TO APPLY TODAY!

A member of our staff will be in contact with you shortly.

Have you tried everything, and are still searching for a solution to Migraine? Clinvest is investigating a new option, but we need your participation to explore new horizons in health.

We are searching for Springfield area applicants to participate in a clinical research study to potentially improve options for those diagnosed with Migraine. The goal of this study is to assess an investigational medication for Migraine. If you’ve ever wished there were more treatment options, then we ask for your help in researching this possibility!

This study is a chronic migraine study for ages 18-75 using a neuromodulator device on your upper arm.  This device will sync via Bluetooth to a smartphone, which will control the device, as well as the location of headache diary. A total of up to 4 visits spanning no longer than 4 months with a 1-month baseline period and up to 3-months open-label period. Compensation may be provided for time and travel.

TO FIND OUT MORE

LEARN MORE ABOUT OUR STUDIES

Clinvest Research is a clinical investigation company based in southwest Missouri. We are constantly seeking participants for clinical trials in order to further options for sufferers of various conditions. Our doctors are a part of a select group of clinics in the U.S. that have been involved in over 200 Phase II-IV clinical research studies sponsored primarily by the pharmaceutical industry or studies created by doctors after patient observation.

Study visits are conducted via outpatient and do not require overnight stays. In fact, we pride ourselves in making your participation in the studies as easy and convenient as possible.

If you qualify and choose to join a study, you will be treated by our team of specialists and may receive study-related care at no cost. Call us at (417) 883-7889 to learn more.